Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Clinics in Liver Disease

Volumn 22, Issue 1, 2018, Pages 1-10

  Younossi, Zobair M ^a,b   Henry, Linda ^c   Bush, Haley ^b   Mishra, Alita ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

Author keywords

Health related quality of life; Mortality; Prevalence; Risk factors

Indexed keywords

DISEASE BURDEN; ETHNICITY; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE ELASTOGRAPHY; METABOLIC DISORDER; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; QUALITY OF LIFE; REVIEW; RISK FACTOR; ULTRASOUND; ECONOMICS; INCIDENCE;

HEALTH CARE COSTS; HUMANS; INCIDENCE; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; QUALITY OF LIFE;

EID: 85031431078     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2017.08.001     Document Type: Review

References (71)

1. Chalasani, N., Younossi, Z., Lavine, J.E., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology, 2017 [Epub ahead of print].
2. Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:1 (2016), 73–84.
3. Ashtari, S., Pourhoseingholi, M.A., Zali, M.R., Non-alcohol fatty liver disease in Asia: prevention and planning. World J Hepatol 7:13 (2015), 1788–1796.
4. Zhu, J.Z., Dai, Y.N., Wang, Y.M., et al. Prevalence of nonalcoholic fatty liver disease and economy. Dig Dis Sci 60:11 (2015), 3194–3202.
5. Chatterjee, A., Basu, A., Chowdhury, A., et al. Comparative analyses of genetic risk prediction methods reveal extreme diversity of genetic predisposition to nonalcoholic fatty liver disease (NAFLD) among ethnic populations of India. J Genet 94:1 (2015), 105–113.
6. Lazo, M., Hernaez, R., Eberhardt, M.S., et al. Prevalence of nonalcoholic fatty liver disease in the United States the third national health and nutrition examination survey, 1988-1994. Am J Epidemiol 178:1 (2013), 38–45.
7. Browning, J.D., Szczepaniak, L.S., Dobbins, R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
8. Schneider, A.L., Lazo, M., Selvin, E., et al. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring) 22:1 (2014), 292–299.
9. Saab, S., Manne, V., Nieto, J., et al. Nonalcoholic fatty liver disease in Latinos. Clin Gastroenterol Hepatol 14:1 (2016), 5–12 [quiz: e9–10].
10. Balakrishnan, M., Kanwal, F., El-Serag, H.B., et al. Acculturation and NAFLD risk among Hispanics of Mexican-origin: findings from the National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol, 2016, 10.1016/j.cgh.2016.09.149.
11. Wagenknecht, L.E., Scherzinger, A.L., Stamm, E.R., et al. Correlates and heritability of nonalcoholic fatty liver disease in a minority cohort. Obesity (Silver Spring) 17 (2009), 1240–1246.
12. Kalia, H.S., Gaglio, P.J., The prevalence and pathobiology of nonalcoholic fatty liver disease in patients of different races or ethnicities. Clin Liver Dis 20:2 (2016), 215–224.
13. Pan, J.J., Fallon, M.B., Gender and racial differences in nonalcoholic fatty liver disease. [review] World J Hepatol 6:5 (2014), 274–283.
14. Kallwitz, E.R., Guzman, G., TenCate, V., et al. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am J Gastroenterol 104:1 (2009), 64–69.
15. Kanwal, F., Kramer, J.R., Duan, Z., et al. Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans. Clin Gastroenterol Hepatol 14:2 (2016), 301–308.e1-2.
16. Carroll, J.F., Fulda, K.G., Chiapa, A.L., et al. Impact of race/ethnicity on the relationship between visceral fat and inflammatory biomarkers. Obesity (Silver Spring) 17 (2009), 1420–1427.
17. Morimoto, Y., Conroy, S.M., Ollberding, N.J., et al. Ethnic differences in serum adipokine and C-reactive protein levels: the multiethnic cohort. Int J Obes (Lond) 38:11 (2014), 1416–1422.
18. Smits, M.M., Ioannou, G.N., Boyko, E.J., et al. Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. J Gastroenterol Hepatol 28:4 (2013), 664–670.
19. Bambha, K., Belt, P., Abraham, M., et al. Nonalcoholic steatohepatitis clinical research network research group ethnicity and nonalcoholic fatty liver disease. Hepatology 55:3 (2012), 769–780.
20. Stepanova, M., Hossain, N., Afendy, A., et al. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes Surg 20:5 (2010), 640–650.
21. Karrar, A., Stepanova, M., Alaparthi, L., et al. Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 30:5 (2015), 900–908.
22. Estep, J.M., Goodman, Z., Sharma, H., et al. Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD. Liver Int 35:4 (2015), 1367–1372.
23. Khan, U.I., Wang, D., Sowers, M.R., et al. Race-ethnic differences in adipokine levels: the study of Women's Health across the Nation (SWAN). Metabolism 61:9 (2012), 1261–1269.
24. Fleischman, M.W., Budoff, M., Zeb, I., et al. NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis. World J Gastroenterol 20:17 (2014), 4987–4993.
25. Foster, T., Anania, F.A., Li, D., et al. The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA). Dig Dis Sci 58:8 (2013), 2392–2398.
26. Dongiovanni, P., Romeo, S., Valenti, L., Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed Res Int, 2015, 2015, 460190.
27. Younossi, Z.M., Otgonsuren, M., Henry, L., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62:6 (2015), 1723–1730.
28. Wong, R.J., Cheung, R., Ahmed, A., Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59:6 (2014), 2188–2195.
29. Mavrogiannaki, A.N., Migdalis, I.N., Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol, 2013, 2013, 450639.
30. Finucane, M.M., Stevens, G.A., Cowan, M.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 377 (2011), 557–567.
31. Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. [review] Nat Rev Gastroenterol Hepatol 10:6 (2013), 330–344.
32. Lonardo, A., Sookoian, S., Chonchol, M., et al. Disease - atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des 19 (2013), 5177–5192.
33. Adams, L.A., Anstee, Q.M., Tilg, H., et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66:6 (2017), 1138–1153.
34. Younossi, Z.M., Stepanova, M., Negro, F., et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) 91:6 (2012), 319–327.
35. Ekstedt, M., Franzen, L.E., Mathiesen, U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:4 (2006), 865–873.
36. Matteoni, C.A., Younossi, Z.M., Gramlich, T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:6 (1999), 1413–1419.
37. Rafiq, N., Bai, C., Fang, Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7:2 (2009), 234–238.
38. Younossi, Z.M., Stepanova, M., Rafiq, N., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53:6 (2011), 1874–1882.
39. Wong, R.J., Aguilar, M., Cheung, R., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148:3 (2015), 547–555.
40. Ertle, J., Dechêne, A., Sowa, J.P., et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128:10 (2011), 2436–2443.
41. Perumpail, R.B., Wong, R.J., Ahmed, A., et al. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci 60:10 (2015), 3142–3148.
42. Yopp, A.C., Choti, M.A., Non-alcoholic steatohepatitis-related hepatocellular carcinoma: a growing epidemic?. Dig Dis 33:5 (2015), 642–647.
43. Ferlay, J.S., Ervik, M., Dikshit, R., et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2013, International Agency for Research on Cancer, Lyon (France).
44. Mittal, S., Sada, Y.H., El-Serag, H.B., et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 13:3 (2015), 594–601.e1.
45. Younossi, Z.M., Gramlich, T., Matteoni, C.A., et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2:3 (2004), 262–265 [Erratum appears in Clin Gastroenterol Hepatol 2004;2(6):522].
46. Otgonsuren, M., Stepanova, M., Gerber, L., et al. Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci 58:4 (2013), 1132–1140.
47. Stepanova, M., Younossi, Z.M., Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10:6 (2012), 646–650.
48. McPherson, S., Hardy, T., Henderson, E., et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 62:5 (2015), 1148–1155.
49. Dulai, P.S., Singh, S., Patel, J., et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 65:5 (2017), 1557–1565.
50. Motamed, N., Rabiee, B., Poustchi, H., et al. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases. Clin Res Hepatol Gastroenterol 41:1 (2017), 31–38.
51. Sinn, D.H., Kang, D., Chang, Y., et al. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut 66:2 (2017), 323–329.
52. Adams, L.A., Lymp, J.F., St Sauver, J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
53. Golabi, P., Sayiner, M., Fazel, Y., et al. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol 10:1 (2016), 63–71.
54. Saadeh, S., Younossi, Z.M., Remer, E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:3 (2002), 745–750.
55. Hashemi, S.A., Alavian, S.M., Gholami-Fesharaki, M., Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Caspian J Intern Med 7:4 (2016), 242–252.
56. Otgonsuren, M., Estep, M.J., Hossain, N., et al. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). J Gastroenterol Hepatol 29:12 (2014), 2006–2013.
57. Cui, J., Ang, B., Haufe, W., et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 41:12 (2015), 1271–1280.
58. Goulart, A.C., Oliveira, I.R., Alencar, A.P., et al. Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Sao Paulo Med J 133:2 (2015), 115–124.
59. Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:2 (2015), 389–397.e10.
60. Younossi, Z., Henry, L., Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 150:8 (2016), 1778–1785.
61. Haflidadottir, S., Jonasson, J.G., Norland, H., et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol, 14, 2014, 166.
62. Golabi, P., Fazel, S., Otgonsuren, M., et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore), 96(9), 2017, e5904.
63. Ekstedt, M., Hagström, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61:5 (2015), 1547–1554.
64. Younossi, Z.M., Stepanova, M., Rafiq, N., et al. Non-alcoholic steatofibrosis is independently associated with both overall mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). J of Hepat, 66(1), 2017, S598.
65. Younossi Z, Stepanova M, Goodman Z, et al. Improvement of hepatic fibrosis in patients with non-alcoholic steatohepatitis (NASH) treated with selonsertib is associated with improvement of patient-reported outcomes (PROS). [Abstract]. EASL. Amsterdam, Netherlands, April 19-23, 2017.
66. Younossi, Z.M., Stepanova, M., Henry, L., et al. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. Liver Int 37:8 (2017), 1209–1218.
67. Golabi, P., Otgonsuren, M., Cable, R., et al. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of health related quality of life (HRQOL). Health Qual Life Outcomes, 14, 2016, 18.
68. Younossi, Z.M., Henry, L., Economic and quality-of-life implications of non-alcoholic fatty liver disease. [review] Pharmacoeconomics 33:12 (2015), 1245–1253.
69. Sayiner, M., Otgonsuren, M., Cable, R., et al. Variables associated with inpatient and outpatient resource utilization among Medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol 51:3 (2017), 254–260.
70. Younossi, Z.M., Zheng, L., Stepanova, M., et al. Clinical outcomes and resource utilisation in Medicare patients with chronic liver disease: a historical cohort study. BMJ Open, 4(5), 2014, e004318.
71. Younossi, Z.M., Blissett, D., Blissett, R., et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64:5 (2016), 1577–1586.